New study tests ilaris to tame rare inflammatory disease
NCT ID NCT07598422
First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 2 times
Summary
This study looks at how well and how safely the drug Ilaris (canakinumab) works for people with Schnitzler's syndrome, a rare condition that causes hives, fever, joint pain, and fatigue. About 5 participants will receive the drug and be monitored for up to 48 weeks. The goal is to see if symptoms improve or go away completely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCHNITZLER SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGKanoya, Kagoshima-ken, 893-0024, Japan
-
Novartis Investigative Site
RECRUITINGOsaka, 5458586, Japan